ANI Pharmaceuticals Inc (NASDAQ:ANIP) insider Arthur Przybyl sold 40,000 shares of the company’s stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $61.83, for a total transaction of $2,473,200.00. Following the completion of the sale, the insider now directly owns 225,706 shares in the company, valued at $13,955,401.98. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of ANI Pharmaceuticals Inc (NASDAQ ANIP) traded down $0.42 during midday trading on Wednesday, reaching $62.04. 109,024 shares of the company were exchanged, compared to its average volume of 145,615. ANI Pharmaceuticals Inc has a 12-month low of $42.23 and a 12-month high of $74.70. The stock has a market capitalization of $727.22, a P/E ratio of 58.53 and a beta of 2.75. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.36 and a quick ratio of 2.39.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.06. ANI Pharmaceuticals had a negative net margin of 0.61% and a positive return on equity of 23.41%. The firm had revenue of $47.30 million for the quarter, compared to the consensus estimate of $52.55 million. During the same period in the prior year, the firm posted $0.84 earnings per share. The firm’s quarterly revenue was up 23.8% compared to the same quarter last year. equities analysts predict that ANI Pharmaceuticals Inc will post 5.17 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. MetLife Investment Advisors LLC purchased a new stake in ANI Pharmaceuticals during the fourth quarter worth $254,000. Jane Street Group LLC purchased a new stake in ANI Pharmaceuticals during the fourth quarter worth $411,000. Millennium Management LLC purchased a new stake in ANI Pharmaceuticals during the fourth quarter worth $210,000. Cornerstone Capital Management Holdings LLC. purchased a new position in ANI Pharmaceuticals during the fourth quarter valued at $895,000. Finally, Nexthera Capital LP purchased a new position in ANI Pharmaceuticals during the fourth quarter valued at $2,701,000. 55.95% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/03/14/ani-pharmaceuticals-inc-anip-insider-sells-2473200-00-in-stock.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.